Comment | Published:

Adverse effects of SGLT2 inhibitors on bone health

Nature Reviews Nephrology (2018) | Download Citation

Sodium–glucose cotransporter 2 (SGLT2) inhibitors provide metabolic and cardiorenal benefits for patients with type 2 diabetes but are associated with a number of safety issues. Here, we discuss evidence suggesting that indirect activation of the FGF23–1,25-dihydroxyvitamin D–parathyroid hormone axis by SGLT2 inhibition might contribute to adverse effects on bone health.

  • Subscribe to Nature Reviews Nephrology for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.


  1. 1.

    DeFronzo, R. A., Norton, L. & Abdul-Ghani, M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 13, 11–26 (2017).

  2. 2.

    Kohan, D. E., Fioretto, P., Tang, W. & List, J. F. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 85, 962–971 (2014).

  3. 3.

    Bilezikian, J. P. et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J. Clin. Endocrinol. Metab. 101, 44–51 (2016).

  4. 4.

    Watts, N. B. et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 101, 157–166 (2016).

  5. 5.

    Blau, J. E. et al. Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight 3, 99123 (2018).

  6. 6.

    Pitts, R. F. & Alexander, R. S. The renal reabsorptive mechanism for inorganic phosphate in normal and acidotic dogs. Am. J. Physiol. 142, 648–662 (1944).

Download references


J.E.B. is supported by funding from the Intramural Research Program of the US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). S.I.T. acknowledges funding from the NIDDK (grant number P30DK072488).

Author information


  1. Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA

    • Jenny E. Blau
  2. Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA

    • Simeon I. Taylor


  1. Search for Jenny E. Blau in:

  2. Search for Simeon I. Taylor in:

Competing interests

J.E.B. declares no competing interests. S.I.T. is a consultant for Ionis Pharmaceuticals, has research support provided to the University of Maryland School of Medicine by Regeneron Pharmaceuticals and has ownership of stock in Celgene, Amgen and Abbott Laboratories.

Corresponding author

Correspondence to Simeon I. Taylor.

About this article

Publication history



Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.